XBiotech Inc (XBIT) Dividend History

XBiotech Inc (XBIT) is a biotechnology company focused on developing and commercializing investigational human therapeutic antibodies for the treatment of various diseases. It is known for its research on immune-based therapies, particularly its proprietary True Human™ monoclonal antibodies. The company's approach emphasizes safety and efficacy through the use of genetically engineered antibodies derived from human sources.

5217 Winnebago Lane, Austin, TX, 78744
Phone: 512-386-2900
Website: http://www.xbiotech.com

Dividend History

Pay Date	Amount	Ex Dividend Date	Record Date
July 23, 2021	$2.10	07/15/2021	07/16/2021

Company News

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

Wolf Haldenstein Adler Freeman & Herz LLP is investigating XBiotech for potential securities law violations after the company announced issues with its Phase II rheumatoid arthritis drug study, leading to a 29% stock price drop.

GlobeNewswire Inc.
XBiotech suspend son programme de rhumatologie

XBiotech has suspended its clinical program on rheumatological conditions pending a review of the results from its recent Phase II study on rheumatoid arthritis. The study did not meet its primary endpoint due to substantial irregularities, and the company is now evaluating the implications of the results before deciding on the next steps for its Natrunix drug candidate in rheumatology.

GlobeNewswire Inc.
XBiotech setzt Rheumatologieprogramm aus

XBiotech has announced that it is halting its clinical program for rheumatological diseases after its recent Phase II trial for rheumatoid arthritis failed to meet its primary endpoint due to significant irregularities that made the results difficult to interpret. The company is now evaluating the data to understand the implications and determine how to proceed with potential future rheumatology studies.

GlobeNewswire Inc.
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - Long-term Forecast to 2033

The global cancer cachexia market is expected to grow from $2.47 billion in 2024 to $3.14 billion by 2028, driven by increased cancer prevalence, enhanced treatment options, and greater awareness among healthcare professionals.

GlobeNewswire Inc.

Featured Companies: ABBV BMY LLY MRK PFE PRGO
Ergebnisse aus randomisierter, doppelt verblindeter Phase-I/II-Studie von XBiotech deuten auf mögliche bahnbrechende Behandlung gegen fortgeschrittenen Bauchspeicheldrüsenkrebs hin

Die Ergebnisse zeigen Tendenz zu geringeren Toxizitäten und besseren Ergebnissen bei Patienten, die eine Kombination aus ONIVYDE/5-FU und gezielter Anti-IL-1alpha-Therapie erhalten Die Ergebnisse zeigen Tendenz zu geringeren Toxizitäten und besseren Ergebnissen bei Patienten, die eine Kombination aus ONIVYDE/5-FU und gezielter Anti-IL-1alpha-Therapie erhalten

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 06:03:52 UTC